Merck KGaA (FRA:MRK) has been given a €103.00 ($119.77) price target by Warburg Research in a research report issued to clients and investors on Tuesday, Borsen Zeitung reports. The firm presently has a “neutral” rating on the healthcare company’s stock. Warburg Research’s price target would indicate a potential upside of 13.06% from the stock’s previous close.
Other equities research analysts also recently issued reports about the stock. DZ Bank reiterated a “neutral” rating on shares of Merck KGaA in a research report on Tuesday, April 2nd. Sanford C. Bernstein set a €108.00 ($125.58) price target on shares of Merck KGaA and gave the company a “neutral” rating in a research report on Monday, April 15th. Barclays set a €82.00 ($95.35) price target on shares of Merck KGaA and gave the company a “sell” rating in a research report on Friday, May 3rd. JPMorgan Chase & Co. set a €100.00 ($116.28) price target on shares of Merck KGaA and gave the company a “neutral” rating in a research report on Monday. Finally, UBS Group set a €104.00 ($120.93) price target on shares of Merck KGaA and gave the company a “neutral” rating in a research report on Monday. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of €101.10 ($117.56).
Shares of MRK opened at €91.10 ($105.93) on Tuesday. Merck KGaA has a twelve month low of €76.60 ($89.07) and a twelve month high of €115.00 ($133.72).
About Merck KGaA
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Further Reading: How to Profit and Limit Losses With Stop Orders
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.